Get the Stockscreener App
7.69
5.41%
-0.44
Aligos Therapeutics Inc stock is traded at $7.69, with a volume of 84,987.
It is down -5.41% in the last 24 hours and down -6.67% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$8.13
Open:
$8.2
24h Volume:
84,987
Relative Volume:
0.73
Market Cap:
$40.87M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.3167
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
+3.08%
1M Performance:
-6.67%
6M Performance:
-72.07%
1Y Performance:
-43.57%
1-Day Range:
$7.54
$8.49
1-Week Range:
$7.09
$8.49
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.69 | 49.16M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Smart tools for monitoring Aligos Therapeutics Inc.’s price actionDaily Investment Ideas with Market Insight - Newser
Is it too late to sell Aligos Therapeutics Inc.Long-Term Allocation Strategy Summary Breakdown - Newser
Will Aligos Therapeutics Inc. price bounce be sustainableFree Conservative Long Term Growth Plans - Newser
Using Bollinger Bands to evaluate Aligos Therapeutics Inc.Weekly High Conviction Trade Setup Analysis - Newser
Why Aligos Therapeutics Inc. stock attracts strong analyst attentionFree Fast Exit and Entry Strategy Guide - Newser
What indicators show strength in Aligos Therapeutics Inc.Intraday Price Forecast Using Volume Models - Newser
Does Aligos Therapeutics Inc. show high probability of reboundSupport and Resistance Zone Summary Chart - Newser
News impact scoring models applied to Aligos Therapeutics Inc.Proven Trading System with Consistent Gains - Newser
Ranking Aligos Therapeutics Inc. among high performing stocks via toolsReal-Time Investment Signal Forecast with AI - Newser
Custom watchlist performance reports with Aligos Therapeutics Inc.Free Entry Alert Based on Volume Spikes - Newser
Can Aligos Therapeutics Inc. rally from current levelsSummary of Reliable Long-Term Trade Models - Newser
What's behind ALGS' volatile quarterly earnings? - AInvest
Will Aligos Therapeutics Inc. stock go up soonExpert-Backed High Yield Stock Watchlist - Newser
Is Aligos Therapeutics Inc. showing signs of accumulationConsistent Gain Plan with AI Support - Newser
How Efficient Is Aligos Therapeutics Inc. at Controlling Operating CostsTrend Reversal Watch with Entry Signals - Newser
Volatility clustering patterns for Aligos Therapeutics Inc.Free Proven Entry Plan With Low Risk Trade - Newser
Aligos Therapeutics Reports Q2 EPS of $1.53, Misses Consensus - AInvest
Aligos 2025 Q2 Earnings Sharp Loss as Net Income Plummets 413% - AInvest
Aligos Therapeutics Reports Q2 2025 Progress and Results - TipRanks
Aligos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54) - TipRanks
Aligos Therapeutics Reports Second Quarter 2025 Financial Results and Progress on Clinical Studies - Quiver Quantitative
Aligos Reports Breakthrough HBV Drug Results: 100% Patient Response in Phase 1 as Pivotal Trial Launches - Stock Titan
Best data tools to analyze Aligos Therapeutics Inc. stockSecure Asset Flow and Trend Pattern Analysis - Newser
How Aligos Therapeutics Inc. stock performs during market volatilitySwing Trade Planning with Consistent Setup - Newser
Real time breakdown of Aligos Therapeutics Inc. stock performanceShort Squeeze Opportunities with Indicators - Newser
Moving Average Trends for Aligos Therapeutics Inc. Stock: What They IndicateRisk-Managed Swing Setup and Signal Analysis - Newser
Is Aligos Therapeutics Inc. a good long term investmentUnlock real-time stock alerts for quick profits - Jammu Links News
Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Analyzing drawdowns of Aligos Therapeutics Inc. with statistical toolsFree Long Hold Safe Return Strategy - Newser
What are analysts’ price targets for Aligos Therapeutics Inc. in the next 12 monthsExceptional trading results - Jammu Links News
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):